United Kingdom · Question · Written question
UIN 42141
Sacituzumab Govitecan
Introduced
3 September 2021
Last action
13 September 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
13 September 2021
Summary
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the National Institute for Health Care Excellence on accelerating the publication of its advice on whether Sacituzumab Govitecan, marketed as Trodelvy,
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
3 September 2021
Written question
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the National Institute for Health Care Excellence on accelerating the publication of its advice on whether Sacituzumab Govitecan, marketed as Trodelvy,
Source: Commons
13 September 2021
Answer
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for scheduling the development of technology appraisal guidance on individual medicines in discussion with the manufacturer. Following discussion with Gilead,...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-09-03/42141
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1352385
- uk · wq-1352385 · source updated 13 September 2021